Physician profile
Rubena Smith
NPI 1649687567
$1,485.86
in general payments reported to CMS, 2019-2025
16 companies · $27.21 in 2025
The $27.21 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $859 · 2020: $259 · 2024: $340 · 2025: $27.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $367.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $179.25 | 2019-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $167.42 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.13 | 2019-2025 | Jardiance |
| Abbott Laboratories | $150.00 | 2024 | Mitraclip |
| Allergan, INC. | $142.40 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $142.07 | 2019-2024 | Farxiga |
| Cvrx, INC. | $129.47 | 2024 | Barostim Neo System |
| Amgen INC. | $108.90 | 2019-2020 | |
| Glaxosmithkline, LLC. | $100.67 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $38.19 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $38.07 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $29.32 | 2019-2020 | |
| Mylan Specialty L.P. | $28.17 | 2019 | |
| Neurocrine Biosciences, INC. | $27.67 | 2024 | Ingrezza |
| Pfizer INC. | $25.86 | 2019-2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $12.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rubena Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.